---
title: "Pemafibrate as a senotherapeutic for COPD via TFEB-driven autophagy and mitophagy regulation"
id: "medrxiv-4-senotherapeutic-role-of-pemafibrate-through-autophagy-mitophagy-regulation-in"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-4-senotherapeutic-role-of-pemafibrate-through-autophagy-mitophagy-regulation-in"
content_type: "clinical_feed_article"
specialty: "Pulmonology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.31.26361865v1?rss=1"
published_at: "2026-09-02T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Pemafibrate as a senotherapeutic for COPD via TFEB-driven autophagy and mitophagy regulation
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-4-senotherapeutic-role-of-pemafibrate-through-autophagy-mitophagy-regulation-in
- **Specialty:** [Pulmonology](https://medichelpline.com/clinical-feed/pulmonology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.31.26361865v1?rss=1)
- **Published At:** 2026-09-02T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Chronic obstructive pulmonary disease (COPD) pathogenesis involves smoking-induced cellular senescence tied to inadequate **autophagy**. Transcription factor EB (**TFEB**) is a central regulator of the autophagy-lysosome pathway and was found reduced in COPD lung epithelial cells in this study. - The investigators tested pemafibrate, a putative **TFEB** inducer, across human bronchial epithelial cells exposed to cigarette smoke (CS) extract, a long-term CS-exposed mouse model, and a retrospective patient cohort comparing pemafibrate versus bezafibrate or fenofibrate. - In vitro, pemafibrate increased **autophagy/mitophagy** flux, restored lysosomal acidification disrupted by CS extract, and reduced cellular senescence; TFEB knockdown attenuated these effects, supporting TFEB involvement. - In mice, pemafibrate upregulated TFEB, reduced alveolar enlargement and airflow obstruction, and prevented the CS-induced increase in static lung compliance after long-term CS exposure. - Bulk RNA sequencing of mouse lungs suggested that pemafibrate’s attenuation of CS-induced cellular senescence may operate through autophagy/mitophagy-related pathways; study reports that RNA-seq data are being deposited to GEO. - A retrospective cohort analysis indicated patients prescribed pemafibrate had an attenuated decline in FEV1.0 compared with patients receiving bezafibrate or fenofibrate. - Ethical approvals were obtained from The Jikei University Ethics Committee for human tissue use and the retrospective cohort; informed consent was obtained for surgical tissue donors and waived for the retrospective cohort per institutional guidelines. - Pemafibrate was provided by Kowa Company, Ltd.; one author declared research support from Kowa. The authors report no other conflicts of interest. - Data deposition (RNA-seq) is in progress; accession number will be provided upon revision. Specific experimental details, numerical outcomes, and statistical measures are reported in the source article and should be consulted there for quantitative results.
## Clinical Analysis & Structured Key Points
Senotherapeutic role of pemafibrate through autophagy/mitophagy regulation in chronic obstructive pulmonary disease | medRxiv Skip to main content Senotherapeutic role of pemafibrate through autophagy/mitophagy regulation in chronic obstructive pulmonary disease View ORCID Profile Sachi Matsubayashi , View ORCID Profile Saburo Ito , Yusuke Hosaka , View ORCID Profile Masahiro Yoshida , View ORCID Profile Tsukasa Kadota , View ORCID Profile Mitsuo Hashimoto , Satoki Hatano , Tomoya Maruyama , Shota Fujimoto , Saiko Nishioka , Shun Inukai , View ORCID Profile Yu Fujita , View ORCID Profile Shunsuke Minagawa , View ORCID Profile Hiromichi Hara , View ORCID Profile Takeo Nakada , Katsutoshi Nakayama , View ORCID Profile Takashi Ohtuska , View ORCID Profile Kazuyoshi Kuwano , View ORCID Profile Jun Araya doi: https://doi.org/10.64898/2026.08.31.26361865 Sachi Matsubayashi 1 Division of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Sachi Matsubayashi Saburo Ito 1 Division of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Saburo Ito For correspondence: saburo.ito.s55{at}gmail.com Yusuke Hosaka 1 Division of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Masahiro Yoshida 1 Division of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Masahiro Yoshida Tsukasa Kadota 2 Department of Medicine, University of California San Francisco, San Francisco, CA, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Tsukasa Kadota Mitsuo Hashimoto 3 Department of Health Science, Nippon Sport Science University, Tokyo, Japan; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Mitsuo Hashimoto Satoki Hatano 1 Division of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Tomoya Maruyama 1 Division of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Shota Fujimoto 1 Division of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Saiko Nishioka 1 Division of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Shun Inukai 1 Division of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Yu Fujita 4 Division of Next-Generation Drug Development, Research Center for Medical Sciences, The Jikei University School of Medicine, Tokyo, Japan; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Yu Fujita Shunsuke Minagawa 1 Division of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Shunsuke Minagawa Hiromichi Hara 1 Division of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Hiromichi Hara Takeo Nakada 5 Division of Thoracic Surgery, Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Takeo Nakada Katsutoshi Nakayama 6 Department of Respiratory Medicine; Akita University Graduate School of Medicine, Akita, Japan; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Takashi Ohtuska 5 Division of Thoracic Surgery, Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Takashi Ohtuska Kazuyoshi Kuwano 7 International University of Health and Welfare Mita Hospital, Tokyo, Japan Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Kazuyoshi Kuwano Jun Araya 1 Division of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Jun Araya Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Inadequate autophagy promotes smoking-induced cellular senescence involved in chronic obstructive pulmonary disease (COPD) pathogenesis. Transcription factor EB (TFEB) is a master regulator of the autophagy-lysosome axis. For the first time, we investigated the therapeutic potential of pemafibrate, a putative TFEB inducer. COPD lung epithelial cells showed reduced TFEB expression. Pemafibrate enhanced autophagy/mitophagy flux and restored lysosomal acidification observed during cigarette smoke (CS) extract exposure in human bronchial epithelial cells, resulting in reduced cellular senescence. TFEB knockdown demonstrated involvement of pemafibrate-induced TFEB in these effects. Pemafibrate induced TFEB expression, mitigated alveolar enlargement and airflow obstruction, and attenuated the CS-induced increase in static lung compliance in a long-term CS-exposed mouse model. It reduced the CS exposure-induced cellular senescence, possibly through autophagy/mitophagy, as suggested by bulk RNA sequencing of mouse lungs. A retrospective cohort study showed that patients given pemafibrate displayed attenuated FEV1.0 decline compared with those given bezafibrate or fenofibrate. In conclusion, pemafibrate is a promising therapeutic agent for COPD, potentially exerting its effects through the regulation of the TFEB-autophagy/mitophagy-lysosome axis. Competing Interest Statement JA is a recipient of support from a collaborative research fund from Kowa Company, Ltd. Kowa Company, Ltd. had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the abstract, or in the decision to present the results. Rest of the authors declare no conflict of interest. Pemafibrate was provided by Kowa Company, Ltd. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The Ethics Committee of The Jikei University School of Medicine (Tokyo, Japan) gave ethical approval for the use of human lung tissues, including those used for human bronchial epithelial cell isolation, obtained from patients undergoing pneumonectomy or lobectomy for primary lung cancer [approval no. 20-153(5443)].Written informed consent was obtained from all participants who underwent surgery as part of this approved ongoing research protocol. The Ethics committee of The Jikei University School of Medicine (Tokyo, Japan) gave ethical approval for the retrospective cohort study [approval no. 34-171(113229). The requirement for informed consent was waived because of the retrospective study design, in accordance with the ethics guidelines of The Jikei University School of Medicine, and an opt-out notice was posted on the hospital website. All clinical data were anonymized to protect participant privacy. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability Data availabitily Raw and processed RNA-seq data generated in this study are being deposited in the NCBI Gene Expression Omnibus. The accession number will be provided upon revision. Funder Information Declared the Project for the Ministry of Education, Culture, Sports, Science, and Technology KAKENHI Grant-in-Aid for Young Scientists , 21K16123 the Project for the Ministry of Education, Culture, Sports, Science, and Technology KAKENHI Grant-in-Aid for Scientific Research B , 22H03082 the Project for the Ministry of Education, Culture, Sports, Science, and Technology KAKENHI Grant-in-Aid for Scientific Research C , 21K08213 The Jikei University Strategic Prioritizing Research Fund , Research Fund 2024 Kowa Company, Ltd. (Tokyo, Japan) , a research grant Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Back to top Previous Next Posted September 02, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Senotherapeutic role of pemafibrate through autophagy/mitophagy regulation in chronic obstructive pulmonary disease Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Senotherapeutic role of pemafibrate through autophagy/mitophagy regulation in chronic obstructive pulmonary disease Sachi Matsubayashi , Saburo Ito , Yusuke Hosaka , Masahiro Yoshida , Tsukasa Kadota , Mitsuo Hashimoto , Satoki Hatano , Tomoya Maruyama , Shota Fujimoto , Saiko Nishioka , Shun Inukai , Yu Fujita , Shunsuke Minagawa , Hiromichi Hara , Takeo Nakada , Katsutoshi Nakayama , Takashi Ohtuska , Kazuyoshi Kuwano , Jun Araya medRxiv 2026.08.31.26361865; doi: https://doi.org/10.64898/2026.08.31.26361865 Share This Article: Copy Citation Tools Senotherapeutic role of pemafibrate through autophagy/mitophagy regulation in chronic obstructive pulmonary disease Sachi Matsubayashi , Saburo Ito , Yusuke Hosaka , Masahiro Yoshida , Tsukasa Kadota , Mitsuo Hashimoto , Satoki Hatano , Tomoya Maruyama , Shota Fujimoto , Saiko Nishioka , Shun Inukai , Yu Fujita , Shunsuke Minagawa , Hiromichi Hara , Takeo Nakada , Katsutoshi Nakayama , Takashi Ohtuska , Kazuyoshi Kuwano , Jun Araya medRxiv 2026.08.31.26361865; doi: https://doi.org/10.64898/2026.08.31.26361865 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (614) Allergy and Immunology (896) Anesthesia (327) Cardiovascular Medicine (4772) Dentistry and Oral Medicine (474) Dermatology (407) Emergency Medicine (643) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1615) Epidemiology (15838) Forensic Medicine (32) Gastroenterology (1195) Genetic and Genomic Medicine (6984) Geriatric Medicine (727) Health Economics (1057) Health Informatics (4989) Health Policy (1427) Health Systems and Quality Improvement (1738) Hematology (582) HIV/AIDS (1336) Infectious Diseases (except HIV/AIDS) (16246) Intensive Care and Critical Care Medicine (1161) Medical Education (663) Medical Ethics (151) Nephrology (721) Neurology (7196) Nursing (364) Nutrition (1074) Obstetrics and Gynecology (1232) Occupational and Environmental Health (1001) Oncology (3575) Ophthalmology (1038) Orthopedics (393) Otolaryngology (446) Pain Medicine (466) Palliative Medicine (139) Pathology (704) Pediatrics (1774) Pharmacology and Therapeutics (733) Primary Care Research (759) Psychiatry and Clinical Psychology (5836) Public and Global Health (9697) Radiology and Imaging (2389) Rehabilitation Medicine and Physical Therapy (1435) Respiratory Medicine (1244) Rheumatology (635) Sexual and Reproductive Health (767) Sports Medicine (577) Surgery (768) Toxicology (107) Transplantation (303) Urology (286)
## Related Clinical Research

- [Triglyceride-Glucose (TyG) Index and Mortality in Non-Diabetic Fibrotic Lung Disease on Antifibrot](https://medichelpline.com/clinical-feed/plos-one-1-association-between-triglyceride-glucose-index-and-all-cause-mortality-in-non.md)
- [No OS Benefit from Adding Chemotherapy to Immunotherapy in PD-L1 TPS ≥50% Advanced NSCLC: Agent-St](https://medichelpline.com/clinical-feed/medrxiv-1-no-overall-survival-benefit-with-adding-chemotherapy-to-immunotherapy-in-pd-l1.md)
- [AURORA: AI analysis of peripheral immune signatures predicting outcomes in extensive-stage SCLC](https://medichelpline.com/clinical-feed/medrxiv-22-aurora-analysing-and-understanding-responses-to-oncological-regimens-with.md)
- [Prognostic Survival Risk Score for Lung Cancer Patients with Type 2 Diabetes: Territory-Wide Retro](https://medichelpline.com/clinical-feed/pubmed-42655935.md) (DOI: 10.1002/cam4.72164)
- [Type 2 Diabetes Risk in Older ANHPI Head and Neck Cancer Survivors in the US](https://medichelpline.com/clinical-feed/pubmed-42665904.md) (DOI: 10.1002/cam4.72227)

## Navigation
- [← Back to Pulmonology Feed](https://medichelpline.com/clinical-feed/pulmonology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.